Originally published by Jazz Pharmaceuticals

To mark International Women’s Day, JAWS (Jazz Association of Women Supporters), the affinity forum created to promote the advancement and impact of women globally in the innovative biotechnology industry, hosted Jenn Harper, the founder and CEO of Cheekbone Beauty Cosmetics for a fireside chat. This inspirational event focused on Ms. Harper’s personal journey, her sustainable, socially conscious beauty brand and her mission to support Indigenous youth. 

At Jazz, we are highly committed to creating a work environment where people can be their authentic selves and where we ensure our people practices promote diversity, equity, inclusion and belonging. Jazz efforts to support women are an ongoing commitment and our Corporate Sustainability and Social Impact strategy is aligned with the UN Sustainable Development Goals. Through our aspirational goals and initiatives, we seek to achieve gender parity globally at the Executive Director and above leadership level to foster increased gender representation in leadership roles. Below is a snapshot of our latest activities to demonstrate gender diversity and our support of women in the workforce.

• Renée Galá named President and Chief Operating Officer
  • Inspiring Inclusion Video Message
• Liz Henderson named Sr. Vice President Technical Operations 
• Jazz Italy Signs Code for Responsible Businesses in Support of Motherhood
• Neena Patil, Chief Legal Officer featured in PharmaVoice discussing her views on leadership, ESG and healthcare
• Heidi Manna, Chief People Officer speaks to the importance of company culture and JazzRemix
• France Gender Equality Index and Jazz Pharmaceuticals Ethical Standards

Jazz Pharmaceuticals

Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases - often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.

More from Jazz Pharmaceuticals